Abstract
Monoamine oxidase enzyme has been developed as a valid target for the treatment of depression. The development of selective and reversible type of monoamine oxidase-A inhibitors still remains a challenge to medicinal chemists pursuing the research towards the search of innovative chemotypes for the management of depressive states. The present chapter focuses on the history of MAO-A inhibitors, structure and biochemistry of MAO-A. It also covers challenges involved in the drug development of MAO-A inhibitors.
Keywords: Adrenaline, Chees effect, Depression, FAD/Dopamine, Inhibitor binding cavity, MAO-A, MAO-B, Moclobemide, Tranylcypromine.
Related Journals
Drug Delivery Letters
Recent Advances in Anti-Infective Drug Discovery
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Bioactive Compounds
Current Drug Delivery
Current Drug Safety
Drug Metabolism and Bioanalysis Letters
Recent Advances in Drug Delivery and Formulation
Reviews on Recent Clinical Trials
Current Drug Targets - Inflammation & Allergy
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms